Business Description
Beijing Tiantan Biological Products Corp Ltd
ISIN : CNE000000WF9
Share Class Description:
SHSE:600161: Class ATotal Employee Number:
5,205Compare
Compare
Traded in other countries / regions
600161.China Index Membership
SSE Composite IndexCSI 500 IndexCSI 500 IndexCSI 300 IndexCSI 500 IndexCSI 300 Index IPO Date
1998-06-16Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.61 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 249.66 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 13.97 | |||||
Beneish M-Score | -1.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.3 | |||||
3-Year EBITDA Growth Rate | 12.2 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | -5.8 | |||||
3-Year Book Growth Rate | 10.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.43 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.83 | |||||
9-Day RSI | 69.31 | |||||
14-Day RSI | 60.03 | |||||
3-1 Month Momentum % | -19.14 | |||||
6-1 Month Momentum % | -26.05 | |||||
12-1 Month Momentum % | -36.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.82 | |||||
Quick Ratio | 4.44 | |||||
Cash Ratio | 2 | |||||
Days Inventory | 419.95 | |||||
Days Sales Outstanding | 63.7 | |||||
Days Payable | 9.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.19 | |||||
Dividend Payout Ratio | 0.49 | |||||
3-Year Dividend Growth Rate | 44.4 | |||||
Forward Dividend Yield % | 1.99 | |||||
5-Year Yield-on-Cost % | 5.3 | |||||
Shareholder Yield % | 0.9 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 41.64 | |||||
Operating Margin % | 28.21 | |||||
Net Margin % | 16.23 | |||||
EBITDA Margin % | 27.48 | |||||
FCF Margin % | -0.39 | |||||
OCF Margin % | 10.43 | |||||
ROE % | 8.38 | |||||
ROA % | 5.89 | |||||
ROIC % | 10.07 | |||||
3-Year ROIIC % | 7.84 | |||||
ROC (Joel Greenblatt) % | 16.57 | |||||
ROCE % | 10.72 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 26.43 | |||||
Forward PE Ratio | 22.26 | |||||
PE Ratio without NRI | 25.15 | |||||
Shiller PE Ratio | 26.98 | |||||
Price-to-Owner-Earnings | 431.67 | |||||
PEG Ratio | 1.69 | |||||
PS Ratio | 4.29 | |||||
PB Ratio | 2.16 | |||||
Price-to-Tangible-Book | 2.6 | |||||
Price-to-Operating-Cash-Flow | 40.99 | |||||
EV-to-EBIT | 16.34 | |||||
EV-to-EBITDA | 16.34 | |||||
EV-to-Revenue | 4.49 | |||||
EV-to-FCF | -1150.19 | |||||
Price-to-GF-Value | 0.54 | |||||
Price-to-Projected-FCF | 2.68 | |||||
Price-to-DCF (Earnings Based) | 1.24 | |||||
Price-to-Median-PS-Value | 0.49 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.81 | |||||
Price-to-Graham-Number | 1.71 | |||||
| Price-to-Net-Current-Asset-Value | 7.23 | |||||
Earnings Yield (Greenblatt) % | 6.12 | |||||
FCF Yield % | -0.09 | |||||
Forward Rate of Return (Yacktman) % | 14.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beijing Tiantan Biological Products Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 5,991.974 | ||
| EPS (TTM) (Â¥) | 0.49 | ||
| Beta | 0.4351 | ||
| 3-Year Sharpe Ratio | -1.09 | ||
| 3-Year Sortino Ratio | -1.23 | ||
| Volatility % | 16.79 | ||
| 14-Day RSI | 60.03 | ||
| 14-Day ATR (Â¥) | 0.431209 | ||
| 20-Day SMA (Â¥) | 12.0625 | ||
| 12-1 Month Momentum % | -36.78 | ||
| 52-Week Range (Â¥) | 11.12 - 22.08 | ||
| Shares Outstanding (Mil) | 1,977.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beijing Tiantan Biological Products Corp Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beijing Tiantan Biological Products Corp Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.150000 Cash Dividend | 2025-09-25 | 19.25 (+0.89%) | ||
| CNY 0.100000 Cash Dividend | 2025-06-20 | 19.14 (+0.00%) | ||
| 1.2:1 Stock Split | 2024-06-20 | 25.10 (-1.60%) | ||
| 1.2:1 Stock Split | 2022-07-15 | 17.28 (-0.88%) | ||
| 1.2:1 Stock Split | 2020-07-15 | 27.51 (-1.96%) | ||
| 1.2:1 Stock Split | 2019-06-14 | 12.87 (-1.11%) | ||
| 1.3:1 Stock Split | 2018-06-22 | 9.61 (-0.08%) | ||
| 1.3:1 Stock Split | 2017-06-19 | 13.79 (-0.60%) | ||
| 1.5:1 Stock Split | 2008-05-09 | 4.47 (+0.00%) | ||
| 1.5:1 Stock Split | 2004-09-28 | 1.48 (-2.10%) |
Show
Entries
Beijing Tiantan Biological Products Corp Ltd Frequently Asked Questions
What is Beijing Tiantan Biological Products Corp Ltd(SHSE:600161)'s stock price today?
The current price of SHSE:600161 is ¥12.95. The 52 week high of SHSE:600161 is ¥22.08 and 52 week low is ¥11.12.
When is next earnings date of Beijing Tiantan Biological Products Corp Ltd(SHSE:600161)?
The next earnings date of Beijing Tiantan Biological Products Corp Ltd(SHSE:600161) is .
Does Beijing Tiantan Biological Products Corp Ltd(SHSE:600161) pay dividends? If so, how much?
The Dividend Yield %  of Beijing Tiantan Biological Products Corp Ltd(SHSE:600161) is 1.19% (As of Today), Highest Dividend Payout Ratio of Beijing Tiantan Biological Products Corp Ltd(SHSE:600161) was 0.49. The lowest was 0.07. And the median was 0.19. The  Forward Dividend Yield % of Beijing Tiantan Biological Products Corp Ltd(SHSE:600161) is 1.99%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Beijing Tiantan Biological Products Corp Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers